Karan Bhalla, MD
Cardiovascular Disease · Pasadena, TXNPI 1407902794
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 61.0% of it on its own, with 43 other manufacturers making up the rest. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 580 payments — averaging $68.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$24K
- Bard Peripheral Vascular, Inc.$5K
- Medtronic$2K
- Novartis$969
- Terumo Medical Corporation$916
- Cardiovascular Systems Inc.$640
- plus $6K from 38 others
Across 245 payments — averaging $6894.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$941K
- Novartis$396K
- Medtronic$151K
- Amgen$59K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$50K
- AstraZeneca$42K
- plus $49K from 2 others
What the payments were for
- Consulting fees$18,93148%
- Speaking & faculty fees$1,2503%
- Travel & lodging$3,90510%
- Food & beverage$15,27539%
- Education$2471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$6,519
- AZUR$675
- Peripheral Orbital Atherectomy System$451
- Coronary Orbital Atherectomy System$451
- COREVALVE EVOLUT R$407
- LUX-DX$357
- EVRSF$327
- ClosureFast$293
- RESONATE$231
- IGT D Peripheral$201
- Hillrom - Carnation Ambulatory Monitor$193
- ATRICLIP LAA EXCLUSION SYSTEM$189
- Farapulse$161
- VIGILANT X4 CRT-D$144
- Perclose ProGlide suture mediated closure system$133
- S-ICD System Magnet$130
- LATITUDE Communicator Power Supply$130
- LATITUDE$123
- Resolute$121
- GENERAL TACHY$119
How this compares
$39,609 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 427 | $542,003 |
| XareltoRivaroxaban | 288 | $342,588 |
| EntrestoSacubitril/Valsartan | 251 | $295,561 |
| Repatha SureclickEvolocumab | 25 | $30,333 |
| Repatha SyringeEvolocumab | 24 | $20,266 |
| VascepaIcosapent Ethyl | 19 | $19,763 |
| FarxigaDapagliflozin Propanediol | 23 | $19,565 |
| JardianceEmpagliflozin | 13 | $17,175 |
| Ranolazine ErRanolazine | 105 | $15,160 |
| Metoprolol Succinate | 668 | $9,550 |
| Icosapent Ethyl | 19 | $7,988 |
| Atorvastatin Calcium | 764 | $7,853 |
| ClopidogrelClopidogrel Bisulfate | 562 | $7,567 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 183 | $6,117 |
| Flecainide Acetate | 160 | $5,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $380 | $542,003427 claims |
| Johnson & JohnsonXarelto | $589 | $342,588288 claims |
| NovartisEntresto | $969 | $295,561251 claims |
| AstraZenecaFarxiga | $434 | $19,56523 claims |
| Boehringer IngelheimJardiance | $201 | $17,17513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Pasadena
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.